13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ST-617 HEAD and NECK

    Acronym: 

    ST 617-101

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Head and Neck
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Head and Neck
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase Ib/2 multicenter, randomised study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ST-617 for the attenuation of oral mucositis in patients receiving chemoradiation for head and neck cancer.

    Lay Summary

    Sponsor / Cooperative group

    Supportive Therapeutics (Pty) Ltd

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Shawgi Sukumaran Recruiting
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Dr Hien Le Recruiting